Summary
Scientists at the Alzheimer's Association International Conference in London have reported encouraging results in testing for and reducing levels of tau protein, a key contributor to Alzheimer's disease. A study by Biogen on the drug diranersen showed a 50%-65% reduction in tau in patients' brains and slowed cognitive decline by up to 50%.